
    
      In this study, we aim to prospectively and randomly evaluate efficacy for changes in clinical
      remission and joint destruction in RA patients in treatment with TCZ monotherapy(SWITCH) and
      in combination therapy with MTX(ADD-ON), and also to investigate the best therapeutic
      approach to achieve discontinuation.
    
  